Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Positive allosteric modulators of nonbenzodiazepine γ-aminobutyric acidA receptor subtypes for the treatment of chronic pain.

Johnstone TBC, Xie JY, Qu C, Wasiak DJ, Hogenkamp DJ, Porreca F, Gee KW.

Pain. 2019 Jan;160(1):198-209. doi: 10.1097/j.pain.0000000000001392.

PMID:
30204648
2.

Role of β2/3-specific GABA-A receptor isoforms in the development of hippocampus kindling epileptogenesis.

Reddy DS, Yoshimura RF, Ramanathan G, Carver C, Johnstone TB, Hogenkamp DJ, Gee KW.

Epilepsy Behav. 2018 May;82:57-63. doi: 10.1016/j.yebeh.2018.02.020. Epub 2018 Mar 26.

PMID:
29587186
3.

Allosteric modulation of nicotinic and GABAA receptor subtypes differentially modify autism-like behaviors in the BTBR mouse model.

Yoshimura RF, Tran MB, Hogenkamp DJ, Ayala NL, Johnstone T, Dunnigan AJ, Gee TK, Gee KW.

Neuropharmacology. 2017 Nov;126:38-47. doi: 10.1016/j.neuropharm.2017.08.029. Epub 2017 Aug 24.

PMID:
28842344
4.

Pharmacological profile of a 17β-heteroaryl-substituted neuroactive steroid.

Hogenkamp DJ, Tran MB, Yoshimura RF, Johnstone TB, Kanner R, Gee KW.

Psychopharmacology (Berl). 2014 Sep;231(17):3517-24. doi: 10.1007/s00213-014-3494-5. Epub 2014 Feb 28.

PMID:
24682501
5.

Limited central side effects of a β-subunit subtype-selective GABAA receptor allosteric modulator.

Yoshimura RF, Tran MB, Hogenkamp DJ, Johnstone TB, Xie JY, Porreca F, Gee KW.

J Psychopharmacol. 2014 May;28(5):472-8. doi: 10.1177/0269881113507643. Epub 2013 Oct 9.

PMID:
24108410
6.

Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors.

Hogenkamp DJ, Ford-Hutchinson TA, Li WY, Whittemore ER, Yoshimura RF, Tran MB, Johnstone TB, Bascom GD, Rollins H, Lu L, Gee KW.

J Med Chem. 2013 Nov 14;56(21):8352-65. doi: 10.1021/jm400704g. Epub 2013 Oct 30.

7.

The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition.

Lotfipour S, Arnold MM, Hogenkamp DJ, Gee KW, Belluzzi JD, Leslie FM.

Neuropharmacology. 2011 Jul-Aug;61(1-2):95-104. doi: 10.1016/j.neuropharm.2011.03.007. Epub 2011 Mar 23.

8.

Allosteric modulation of related ligand-gated ion channels synergistically induces long-term potentiation in the hippocampus and enhances cognition.

Johnstone TB, Gu Z, Yoshimura RF, Villegier AS, Hogenkamp DJ, Whittemore ER, Huang JC, Tran MB, Belluzzi JD, Yakel JL, Gee KW.

J Pharmacol Exp Ther. 2011 Mar;336(3):908-15. doi: 10.1124/jpet.110.176255. Epub 2010 Dec 15.

9.

Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia.

Gee KW, Tran MB, Hogenkamp DJ, Johnstone TB, Bagnera RE, Yoshimura RF, Huang JC, Belluzzi JD, Whittemore ER.

J Pharmacol Exp Ther. 2010 Mar;332(3):1040-53. doi: 10.1124/jpet.109.161885. Epub 2009 Nov 25.

10.

Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats.

Yoshimura RF, Hogenkamp DJ, Li WY, Tran MB, Belluzzi JD, Whittemore ER, Leslie FM, Gee KW.

J Pharmacol Exp Ther. 2007 Dec;323(3):907-15. Epub 2007 Sep 14.

PMID:
17873105
11.

Enaminone amides as novel orally active GABAA receptor modulators.

Hogenkamp DJ, Johnstone TB, Huang JC, Li WY, Tran M, Whittemore ER, Bagnera RE, Gee KW.

J Med Chem. 2007 Jul 12;50(14):3369-79. Epub 2007 Jun 16.

PMID:
17571865
12.

Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators.

Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE, Gee KW.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8059-64. Epub 2007 Apr 30.

13.

Reversible lipidization for the oral delivery of leu-enkephalin.

Wang J, Hogenkamp DJ, Tran M, Li WY, Yoshimura RF, Johnstone TB, Shen WC, Gee KW.

J Drug Target. 2006 Apr;14(3):127-36.

PMID:
16753826
14.

Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.

Ilyin VI, Pomonis JD, Whiteside GT, Harrison JE, Pearson MS, Mark L, Turchin PI, Gottshall S, Carter RB, Nguyen P, Hogenkamp DJ, Olanrewaju S, Benjamin E, Woodward RM.

J Pharmacol Exp Ther. 2006 Sep;318(3):1083-93. Epub 2006 May 25.

PMID:
16728593
15.

3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.

Yang J, Gharagozloo P, Yao J, Ilyin VI, Carter RB, Nguyen P, Robledo S, Woodward RM, Hogenkamp DJ.

J Med Chem. 2004 Mar 11;47(6):1547-52.

PMID:
14998340
16.

Modifying quinolone antibiotics yields new anxiolytics.

Johnstone TB, Hogenkamp DJ, Coyne L, Su J, Halliwell RF, Tran MB, Yoshimura RF, Li WY, Wang J, Gee KW.

Nat Med. 2004 Jan;10(1):31-2. Epub 2003 Nov 30.

PMID:
14647497
17.
18.

Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids.

Vanover KE, Edgar DM, Seidel WF, Hogenkamp DJ, Fick DB, Lan NC, Gee KW, Carter RB.

J Pharmacol Exp Ther. 1999 Dec;291(3):1317-23.

PMID:
10565857
19.

Substituted 3beta-phenylethynyl derivatives of 3alpha-hydroxy-5alpha-pregnan-20-one: remarkably potent neuroactive steroid modulators of gamma-aminobutyric acidA receptors.

Hawkinson JE, Acosta-Burruel M, Yang KC, Hogenkamp DJ, Chen JS, Lan NC, Drewe JA, Whittemore ER, Woodward RM, Carter RB, Upasani RB.

J Pharmacol Exp Ther. 1998 Oct;287(1):198-207.

PMID:
9765338
20.

Synthesis and in vitro activity of 3 beta-substituted-3 alpha-hydroxypregnan-20-ones: allosteric modulators of the GABAA receptor.

Hogenkamp DJ, Tahir SH, Hawkinson JE, Upasani RB, Alauddin M, Kimbrough CL, Acosta-Burruel M, Whittemore ER, Woodward RM, Lan NC, Gee KW, Bolger MB.

J Med Chem. 1997 Jan 3;40(1):61-72.

PMID:
9016329
21.

3 alpha-Hydroxy-3 beta-trifluoromethyl-5 alpha-pregnan-20-one (Co 2-1970): a partial agonist at the neuroactive steroid site of the gamma-aminobutyric acidA receptor.

Hawkinson JE, Drewe JA, Kimbrough CL, Chen JS, Hogenkamp DJ, Lan NC, Gee KW, Shen KZ, Whittemore ER, Woodward RM.

Mol Pharmacol. 1996 May;49(5):897-906.

PMID:
8622640

Supplemental Content

Loading ...
Support Center